This review highlights promising protein-based HIV entry inhibitors that have demonstrated efficacy in preclinical studies, and discusses ongoing efforts to optimize their valency, avidity, specificity, serum half-life, effector functions, and production platforms to improve their therapeutic potential and economic feasibility.
Rashmi Kumariya, Carole A. Bewley· Biomolecules· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.